Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1441271
This article is part of the Research Topic New potential biomarkers and cellular strategies for the study of prostate cancer and testicular cancer cells View all articles

Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010

Provisionally accepted
Ran He Ran He 1Youjun Ye Youjun Ye 2*Qilei Zhu Qilei Zhu 2*Changsheng Xie Changsheng Xie 3*
  • 1 The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China
  • 2 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
  • 3 Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

The final, formatted version of the article will be published soon.

    The Systemic Immuno-Inflammation Index (SII) is a crucial clinical measure of inflammation, and there is currently no solid evidence linking SII to an increased risk of prostate cancer (PCa). Through the analysis of serum total prostate-specific antigen (tPSA), free prostatespecific antigen (fPSA), and the tPSA/fPSA (fPSA%) ratio, this study sought to investigate the relationship between SII and PCa risk among the U.S. elderly.Elderly male participants were gathered from the NHANES database between 2001 and 2010.SII was calculated by platelet count * neutrophil count/lymphocyte count. High risk individuals for prostate cancer were defined as those with tPSA > 4 ng/ml and fPSA% < 16%. Multivariate

    Keywords: systemic immune-inflammation index, Total prostate-specific antigen, free prostatespecific antigen, fPSA%, prostate cancer, Cross-sectional study

    Received: 31 May 2024; Accepted: 05 Sep 2024.

    Copyright: © 2024 He, Ye, Zhu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Youjun Ye, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
    Qilei Zhu, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
    Changsheng Xie, Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.